
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

Apellis Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Deep Track Capital, LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power
0.00
Shared Voting Power
6
4,532,374.00
Sole Dispositive Power
7
0.00
Shared Dispositive Power
8
4,532,374.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,532,374.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

3.55 %

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

CAYMAN ISLANDS

Sole Voting Power

0.00

Shared Voting Power

4,532,374.00

Sole Dispositive Power

0.00

Shared Dispositive Power

4,532,374.00

Aggregate Amount Beneficially Owned by Each Reporting Person

4,532,374.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)
3.55 %
Type of Reporting Person (See Instructions)
12
CO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1
David Kroin
Check the appropriate box if a member of a Group (see instructions)

2
 (a)
 (b)

3
Sec Use Only
Citizenship or Place of Organization

4
UNITED STATES

Sole Voting Power

5
0.00

Number of
Shares

6
Shared Voting Power
4,532,374.00

Beneficially
Owned by
Each

7
Sole Dispositive Power
0.00

Reporting
Person
With:

8
Shared Dispositive
Power
4,532,374.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9
4,532,374.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11
3.55 %

Type of Reporting Person (See Instructions)

12
HC, IN

SCHEDULE 13G

Item 1.

Name of issuer:

(a)
Apellis Pharmaceuticals, Inc.

Address of issuer's principal executive offices:

(b)
100 FIFTH AVENUE, WALTHAM, MA, 02451

Item 2.

Name of person filing:

(a)

(i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin

Address or principal business office or, if none, residence:

(b)

(i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

Citizenship:

(c)

(i) Delaware (ii) Cayman Islands (iii) United States

Title of class of securities:

(d)

Common Stock, \$0.0001 par value per share

(e)

CUSIP No.:

Item 4.

Ownership

Amount beneficially owned:

(a)

4,532,374

Percent of class:

(b)

3.55% %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

4,532,374

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

4,532,374

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of

the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature: /s/ David Kroin

Name/Title: David Kroin, Managing Member of the General
Partner of the Investment Adviser

Date: 05/15/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature: /s/ David Kroin

Name/Title: David Kroin, Director

Date: 05/15/2026

David Kroin

Signature: /s/ David Kroin

Name/Title: David Kroin

Date: 05/15/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of March 31, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 127,829,909 Common Stock outstanding as of February 17, 2026, according to the issuer's 10-K filed with the SEC on February 24, 2026. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k). The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin